In the context of MASLD, FFAR4 activation may reduce hepatic inflammation and fibrosis by attenuating inflammatory responses and improving insulin sensitivity [115,116]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.